| Hillary Maren Epstein, MD | |
|
7601 Osler Dr, Towson, MD 21204-7700 | |
| (410) 337-1724 | |
| Not Available |
| Full Name | Hillary Maren Epstein |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 17 Years |
| Location | 7601 Osler Dr, Towson, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376744656 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chesapeake Urology Associates Llc | 4789673393 | 134 |
News Archive
Today, Lung Cancer Alliance (LCA) proudly announced that The Honorable Michael G. Oxley has agreed to join its Board of Directors. Oxley, a former Member of Congress, joins LCA, the only national organization dedicated solely to all those either living with or at risk for lung cancer, as it prepares to begin its sixth year of patient support and advocacy headquartered in Washington, DC.
In a round-up of events from the XIX International AIDS Conference on the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Trevor DeWitt, new media communications officer for the foundation, notes that the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday released results "showing broad gains in the number of people receiving HIV treatment."
DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today that AP-HP (Assistance Public - Hôpitaux de Paris) sponsor of the ARACHILD study presented at the EAACI Congress a late breaking oral presentation on safety and efficacy data after six months of epicutaneous immunotherapy in peanut allergy using Viaskin Peanut.
Antigenics Inc. today announced that effective immediately it is changing its name to Agenus Inc. The company's stock will continue to be traded on NASDAQ under the symbol AGEN. The new name reflects the broadening of the company's product portfolio of clinical candidates beyond autologous antigen-based vaccines, as well as its commitment to actively pursuing licensing opportunities to leverage its development capabilities and expand its product portfolio.
The role of dietary fructose in the development of obesity and fatty liver diseases remains controversial, with previous studies indicating that the problems resulted from fructose and a diet too high in calories.
› Verified 3 days ago
| Entity Name | Chesapeake Urology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700153921 PECOS PAC ID: 4789673393 Enrollment ID: O20111216000464 |
News Archive
Today, Lung Cancer Alliance (LCA) proudly announced that The Honorable Michael G. Oxley has agreed to join its Board of Directors. Oxley, a former Member of Congress, joins LCA, the only national organization dedicated solely to all those either living with or at risk for lung cancer, as it prepares to begin its sixth year of patient support and advocacy headquartered in Washington, DC.
In a round-up of events from the XIX International AIDS Conference on the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Trevor DeWitt, new media communications officer for the foundation, notes that the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday released results "showing broad gains in the number of people receiving HIV treatment."
DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today that AP-HP (Assistance Public - Hôpitaux de Paris) sponsor of the ARACHILD study presented at the EAACI Congress a late breaking oral presentation on safety and efficacy data after six months of epicutaneous immunotherapy in peanut allergy using Viaskin Peanut.
Antigenics Inc. today announced that effective immediately it is changing its name to Agenus Inc. The company's stock will continue to be traded on NASDAQ under the symbol AGEN. The new name reflects the broadening of the company's product portfolio of clinical candidates beyond autologous antigen-based vaccines, as well as its commitment to actively pursuing licensing opportunities to leverage its development capabilities and expand its product portfolio.
The role of dietary fructose in the development of obesity and fatty liver diseases remains controversial, with previous studies indicating that the problems resulted from fructose and a diet too high in calories.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hillary Maren Epstein, MD 965 Fell St, Baltimore, MD 21231-3505 Ph: () - | Hillary Maren Epstein, MD 7601 Osler Dr, Towson, MD 21204-7700 Ph: (410) 337-1724 |
News Archive
Today, Lung Cancer Alliance (LCA) proudly announced that The Honorable Michael G. Oxley has agreed to join its Board of Directors. Oxley, a former Member of Congress, joins LCA, the only national organization dedicated solely to all those either living with or at risk for lung cancer, as it prepares to begin its sixth year of patient support and advocacy headquartered in Washington, DC.
In a round-up of events from the XIX International AIDS Conference on the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Trevor DeWitt, new media communications officer for the foundation, notes that the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday released results "showing broad gains in the number of people receiving HIV treatment."
DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today that AP-HP (Assistance Public - Hôpitaux de Paris) sponsor of the ARACHILD study presented at the EAACI Congress a late breaking oral presentation on safety and efficacy data after six months of epicutaneous immunotherapy in peanut allergy using Viaskin Peanut.
Antigenics Inc. today announced that effective immediately it is changing its name to Agenus Inc. The company's stock will continue to be traded on NASDAQ under the symbol AGEN. The new name reflects the broadening of the company's product portfolio of clinical candidates beyond autologous antigen-based vaccines, as well as its commitment to actively pursuing licensing opportunities to leverage its development capabilities and expand its product portfolio.
The role of dietary fructose in the development of obesity and fatty liver diseases remains controversial, with previous studies indicating that the problems resulted from fructose and a diet too high in calories.
› Verified 3 days ago
David A Brinker, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 7601 Osler Dr, Towson, MD 21204 Phone: 410-337-1000 | |
Zhen Fan, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 7601 Osler Dr, Towson, MD 21204 Phone: 410-337-1000 | |
Steven R Axe, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 7601 Osler Dr, Towson, MD 21204 Phone: 410-337-1000 | |
Fowza Taqi, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 7601 Osler Dr, Towson, MD 21204 Phone: 410-377-1000 | |
James W Eagan Jr., M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 7601 Osler Dr, Towson, MD 21204 Phone: 410-337-1000 | |
Dr. Clarence D Miller, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1026 Green Acre Rd, Towson, MD 21286 Phone: 410-821-1673 |